Search Result
Results for "
platelet-activating factor (PAF)
" in MedChemExpress (MCE) Product Catalog:
2
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P2606
-
-
-
- HY-137257
-
-
-
- HY-106062
-
-
-
- HY-101675
-
-
-
- HY-10164
-
-
-
- HY-N3054
-
-
-
- HY-122126
-
-
-
- HY-100153
-
-
-
- HY-105198
-
-
-
- HY-134235
-
-
-
- HY-101833
-
-
-
- HY-19205A
-
|
|
Lipoxygenase
|
Inflammation/Immunology
|
|
CMI-392 is a dual 5-lipoxygenese inhibitor and platelet-activating factor (PAF) receptor antagonist with IC50s of 100 and 10 nM, respectively.
|
-
-
- HY-171253
-
-
-
- HY-N3055
-
|
|
Apoptosis
|
Cancer
|
|
Pinusolide is a known platelet-activating factor (PAF) receptor binding antagonist. Pinusolide not only decreases the proliferation activity of tumor cells but specifically induces apoptosis .
|
-
-
- HY-106833A
-
-
-
- HY-116120
-
-
-
- HY-N1208
-
|
O-Acetylspiradine G; Spiradine G acetate
|
Others
|
Cardiovascular Disease
|
|
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activating factor (PAF)-induced platelet aggregation .
|
-
-
- HY-123505
-
-
-
- HY-W040221
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Metabolic Disease
|
|
Butanoyl PAF, a compound closely related to Azelaoyl PC (HY-134154), maintains over 10% of the agonist potency of platelet-activating factor (PAF). Butanoyl PAF's concentration in oxidized low-density lipoprotein surpasses that of enzymatically generated PAF by more than 100-fold .
|
-
-
- HY-130345
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
|
-
-
- HY-134101
-
-
-
- HY-N8218
-
-
-
- HY-125309
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Others
|
|
ABT-299 is a prodrug of a platelet-activating factor (PAF) antagonist that exhibits significant inhibitory activity on PAF-induced β-platelet globulin release in vitro after in vivo administration in humans, an effect that may be partially attributed to the pyridine-N-oxide metabolite.
|
-
-
- HY-133003
-
-
-
- HY-108634
-
Apafant
1 Publications Verification
WEB 2086
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
Apafant (WEB 2086) is a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM. Apafant increases the gene expression of PAF-r, α-globin, β-globin, decreases the c-myb gene expression. Apafant shows a protective effect on alkyl-PAF-mediated lethalit .
|
-
-
- HY-128694
-
|
SR27417
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Foropafant (SR27417) highly potent, competitive, selective and orally active antagonist of platelet-activating factor (PAF) receptor, with a Ki value of 57 pM for [ 3H]PAF binding, at least 5-fold lower than that of unlabeled PAF itself. Foropafant potently inhibits PAF-induced aggregation of rabbit and human platelets .
|
-
-
- HY-141581
-
-
-
- HY-108908A
-
-
-
- HY-N3643
-
-
-
- HY-N2247A
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Metabolic Disease
|
|
(+)-Guaiacin is a compound extracted of the bark of Machilus wangchiana Chun. (Lauraceae). (+)-Guaiacin shows potent in vitro activities against the release of β-glucuronidase in rat polymorphonuclear leukocytes (PMNs) induced by platelet-activating factor (PAF) .
|
-
-
- HY-121007
-
|
Web2170
|
Platelet-activating Factor Receptor (PAFR)
|
Others
|
|
Bepafant (Web2170) is a platelet-activating factor (PAF) antagonist that protects against anaphylactic lethality in active and passive anaphylaxis models in mice and guinea pigs in a dose-dependent manner and attenuates bronchoconstriction and blood pressure changes in anaphylaxis.
|
-
-
- HY-134070
-
|
ET-18-O-OCH3
|
TNF Receptor
|
Inflammation/Immunology
|
|
2-O-Methyl PAF C-16 (ET-18-O-OCH3), a structural analog of the mediator of inflammation platelet-activating factor (PAF), is a cytotoxic ether lipid. 2-O-Methyl PAF C-16 stimulates TNF-α release in murine macrophages .
|
-
-
- HY-N11920
-
-
-
- HY-108635
-
|
PAF (C16)
|
p38 MAPK
MEK
ERK
Endogenous Metabolite
|
Cardiovascular Disease
Inflammation/Immunology
|
|
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .
|
-
-
- HY-U00040
-
-
-
- HY-101594
-
-
-
- HY-19126
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Infection
Cardiovascular Disease
|
|
CL-184005 is an antagonist for platelet-activating factor (PAF), that inhibits the PAF-induced platelet aggregation with IC50 of 600 nM and 510 nM, in human and rabbit platelet-rich plasma. CL-184005 protects the rats from endotoxin-induced gastrointestinal damage and hypotension. CL-184005 exhibits potential attenuating Gram-negative bacterial sepsis .
|
-
-
- HY-N12995
-
-
-
- HY-141612
-
-
-
- HY-W027544
-
|
7-Methoxycoumarin-4-acetic acid
|
Fluorescent Dye
|
Others
|
|
MCA (7-Methoxycoumarin-4-acetic acid) is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
|
-
-
- HY-19097
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Ro 24-4736 is a potent, selective, p.o.-active platelet-activating factor (PAF) antagonist with a long duration of action. Ro-24-4736 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
-
- HY-N2892
-
|
Aristololactam A IIIa; Sch 546909
|
DYRK
|
Cardiovascular Disease
Cancer
|
|
Aristolactam A IIIa (Sch 546909) is an aristolactam-type alkaloid that can be isolated from Glycosmis chlorosperma. Aristolactam A IIIa is a DYRK1A Inhibitor. Aristolactam A IIIa inhibits platelet aggregation induced by arachidonic acid (AA), collagen and platelet-activating factor (PAF). Aristolactam A IIIa has strong cytotoxic effect on HeLa cells .
|
-
-
- HY-123397
-
-
-
- HY-19084
-
-
-
- HY-N3436
-
-
-
- HY-132190
-
|
1-O-Hexa-decyl-2-acetyl-sn-glycero-3-phospho(N,N,N-trimethyl)-hexanolamine
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Hexanolamino PAF C-16 (1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho (N,N,N trimethyl) hexanolamine) is a Platelet-activating Factor Receptor (PAFR) Modulator with partial agonist activity. Hexanolamino PAF C-16 induces platelet aggregation and macrophage production but fails to increase [Ca2+]i in platelets, suggesting that PAF receptors may interact with PAF receptors through Ca 2+-dependent and -independent pathways. Related to platelet aggregation .
|
-
-
- HY-121394
-
-
-
- HY-126551
-
|
|
LDLR
Platelet-activating Factor Receptor (PAFR)
Calcium Channel
|
Metabolic Disease
|
|
Butenoyl-PAF is a phospholipid analog of platelet activating factor (PAF-like) that is generated in oxidized low-density lipoprotein (DLDR). Butenoyl-PAF can activate cells that express human PAF receptors, such as neutrophils, monocytes, and platelets, and it stimulates an increase in intracellular calcium ion concentration .
|
-
-
- HY-101654
-
-
-
- HY-121377
-
-
- HY-W027544S
-
|
7-Methoxycoumarin-4-acetic acid-d3
|
Isotope-Labeled Compounds
Fluorescent Dye
|
Others
|
|
MCA-d3 (7-Methoxycoumarin-4-acetic acid3) is the deuterium labeled MCA (HY-W027544) . MCA is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
|
-
- HY-109897
-
-
- HY-119035
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
R-75317 is a specific platelet-activating factor (PAF) antagonist. R-75317 can prevent the decline in creatinine clearance (Ccr) in a rat model of glomerulonephritis induced by the injection of antibodies extracted from rabbits against rat glomerular basement membrane (GBM) antigens, delay the onset of proteinuria, and improve glomerular hypertrophy, mesangial matrix proliferation, and interstitial fibrosis. R-75317 may be useful in the study of glomerulonephritis .
|
-
- HY-100316
-
-
- HY-124887
-
-
- HY-117636
-
-
- HY-101731
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Ki values of 34 nM and 37 nM, respectively .
|
-
- HY-19121A
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cancer
|
|
TCV-309 chloride is a potent and specific platelet activating factor (PAF) antagonist. TCV-309 chloride specifically inhibits PAF-induced aggregation of rabbit and human platelets, and [3H]PAF binding to rabbit platelet microsomes with IC50 values of 33 nM, 58 nM and 27 nM, respectively. TCV-309 chloride has beneficial effects in anaphylactic shock .
|
-
- HY-141570S
-
-
- HY-19121
-
-
- HY-100164
-
|
MKS 492
|
Phosphodiesterase (PDE)
|
Inflammation/Immunology
|
|
SDZ-MKS 492 (MKS 492) is a selective inhibitor of cyclic GMP-inhibited phosphodiesterase (type III PDE). SDZ-MKS 492 inhibits antigen- or platelet activating factor (PAF)-induced bronchoconstriction and allergic reactions in guinea pigs and rats .
|
-
- HY-N12707
-
-
- HY-N14932
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Aggreceride A is a platelet aggregation inhibitor. Aggreceride A shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
|
-
- HY-N9300
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
1,6-Dihydro-4,7-epoxy-1-methoxy-3,4-methylenedioxy-6-oxo-3,8-lignan, a lignan derivative from the ethyl acetate soluble fraction of twigs of Magnolia denudate (Magnoliaceae), exhibits anti-platelet-activating factor (PAF) activity. PAF is a potent lipid mediator in inflammation and asthma .
|
-
- HY-N14933
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Aggreceride B is a platelet aggregation inhibitor. Aggreceride B shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
|
-
- HY-N14934
-
|
|
Platelet-activating Factor Receptor (PAFR)
|
Cardiovascular Disease
|
|
Aggreceride C is a platelet aggregation inhibitor. Aggreceride C shows an inhibitory activity against aggregation induced by Adenosine 5'-diphosphate (ADP) (HY-W010918), Arachidonic acid (HY-109590) and PAF (platelet activating factor), but was less active against aggregation induced by collagen .
|
-
- HY-W923483
-
|
1-O-Hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine
|
Platelet-activating Factor Receptor (PAFR)
Endogenous Metabolite
|
Cardiovascular Disease
|
|
C16-18:1 PC (1-O-Hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine), also known as 1-O-hexadecyl-2-oleoyl-sn-glycero-3-phosphocholine (HOPC), is a member of the platelet-activating factor (PAF) family of glycerophospholipids and serves as a pro-inflammatory lipid mediator with diverse biological and pharmacological effects; it features a mono-ether structure with an oleoyl chain (18:1) ester-linked at the sn-2 position and a hexadecyl chain (16:0) ether-linked at the sn-1 position.
|
-
- HY-106837
-
|
Y 24180
|
Platelet-activating Factor Receptor (PAFR)
|
Inflammation/Immunology
|
|
Israpafant (Y-24180) is a potent, selective and long-acting platelet activation factor (PAF) receptor antagonist with IC50s of 0.84 nM and 3.84 nM against PAF-induced human and rabbit platelet aggregation, respectively. Israpafant stimulates both extracellular Ca 2+ influx and intracellular Ca 2+ release in prostate cancer cells. Israpafant suppresses the allergic cutaneous reactions including eosinophilia, cytokine production, edema and erythema in mice .
|
-
- HY-142670
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-5 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-5 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 32) .
|
-
- HY-142669
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-4 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-4 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2021228159A1, compound 38) .
|
-
- HY-163101
-
|
|
Platelet-activating Factor Receptor (PAFR)
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma .
|
-
- HY-142779
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-11 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-11 has the potential for the research of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease (extracted from patent WO2014114249A1, compound E145) .
|
-
- HY-142778
-
|
|
Phospholipase
|
Neurological Disease
Metabolic Disease
|
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4) .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-W027544
-
|
7-Methoxycoumarin-4-acetic acid
|
Fluorescent Dyes/Probes
|
|
MCA (7-Methoxycoumarin-4-acetic acid) is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
|
| Cat. No. |
Product Name |
Target |
Research Area |
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-141570S
-
|
|
|
Lyso-PAF C-16-d4 is the deuterium labeled Lyso-PAF C-16[1].
|
-
-
- HY-W027544S
-
|
|
|
MCA-d3 (7-Methoxycoumarin-4-acetic acid3) is the deuterium labeled MCA (HY-W027544) . MCA is a Coumarin (HY-N0709) derivative. MCA quantitates platelet-activating factor (PAF) by high-performance liquid chromatography with fluorescent detection. MCA can modify FRET peptide substrates for analyzing protease activities .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-130345
-
|
|
|
Phospholipids
|
|
C18-PAF, octadecane PAF, is the ligand of platelet-activating factor and PAF G protein-coupled receptor (PAFR). C18-PAF has renovasodilator properties and antihypertensive lipid properties. C18-PAF increases renal blood flow and causes dose-dependent systemic hypotension .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
